Kornimate/medical-research-clean huggingface dataset:
critical illness neuromuscular abnormalities in neurocritical care patients

Conditions: Muscle Weakness; Critical Illness

Summary: the aim of this research is to investigate critical illness neuromuscular abnormalities in neurocritical care patients.

since 1984, the problem of critical illness neuromuscular abnormalities (cinmas) has attracted considerable interest. according to these studies, cinmas include the muscular weakness that accompanies critical illness resulting from polyneuropathy and/or myopathy and can be seen in 25-85% of cases of critically ill patients. clinically, cinmas present as symmetric flaccid tetraparesis and difficulty weaning off mechanical lung ventilation. however, these data are derived from treating non-specialized intensive care unit (icu) patients. in this research, we wished to investigate cinmas in neurocritical care patients. from day one of the patients' participation in the research and until a discharge from the icu (or death), daily neurological surveys and weekly nerve conduction studies were performed. based on the results of each nerve conduction study, an index of neuromuscular damage was noted to evaluate the severity of the cinmas. needle electromyography and muscle biopsy were not used

Eligibility criteria:
inclusion criteria: * age: 16 years and older * acute primary cerebral pathology * mechanical ventilation * signs of systemic inflammatory response * exclusion of the possibility of an initial pathology of the spinal cord, peripheral nervous system and muscles in past medical history exclusion criteria: * brain stem or bilateral hemispheric lesions with tetraparesis at the onset of illness * inability to perform high-grade nerve conduction studies

Keywords: neuromuscular diseases critical illness mechanical ventilation phrenic nerve nerve conduction studies
qplus pediatric reference interval

Conditions: Pediatric ALL; Healthy

Summary: evaluation of coagulation results reported by the qplus quantra system to determine pediatric reference range intervals.

single center observational study of the pediatric patient population (\< 18yrs) with normal coagulation function to determine the reference range interval for the clotting parameters reported by the quantra qplus system.

Eligibility criteria:
inclusion criteria: * \<18yrs * scheduled for procedure requiring anesthesia * access to blood sampling * consented exclusion criteria: * \>18yrs of age * pre-term babies * patients with know hematological disorders * difficult to obtain blood sampling * has received a blood product transfusion within the last 24hrs. * legal guardian unwilling to consent

Keywords: qplus quantra pediatric reference range
a randomized controlled study of medical-education-community collaborated intervention in children with adhd

Conditions: Attention Deficit Hyperactivity Disorder

Summary: this study is designed to test if the medical-education-community collaborated intervention can reduce the symptoms of children with attention deficit hyperactivity disorder (adhd) compared to routine clinical care. investigators will also evaluate if the intervention will positively affect organizational skills and academic achievement compared to controls.


Eligibility criteria:
inclusion criteria: * diagnosed with adhd * doctor rated snap-iv inattention of hyperactivity/impulsivity score\>12 * full-scale intelligence quotient\>=80 (wechsler intelligence scale for children-iv) exclusion criteria: * accepting any type of psychological treatment during the intervention * comorbid with epileptic disorder or other existing physical disorder, tourette syndrome, autism spectrum disorder, learning disorder, mood disorder, psychiatric disorder, or under suicidal risk * attending any other clinical research at the same time
utility of vancomycin loading: a pharmacokinetic analysis in critically ill patients

Conditions: Infection

Summary: the goal of this clinical research study is to learn if giving a larger than normal "loading dose" of the antibiotic vancomycin before starting standard vancomycin dosing can help patients reach and maintain the needed blood-level of the antibiotic during treatment.

the study drug: vancomycin is an antibiotic used to treat serious, life-threatening infections caused by bacteria. researchers want to find the best and most effective dose and blood-level of the drug that may have the best effect against bacteria. study drug administration: if your doctor believes you are eligible, and you agree to take part in this study, you will be given a "loading dose" of vancomycin that is about twice as large as the standard dose. the dose amounts will be based on your body weight. doses can be given every 8-12 hours, depending on your level of kidney function. study procedures: blood (about 1 teaspoon each time) will be drawn for pharmacokinetic (pk) testing and to check your kidney function. pk testing measures the amount of study drug in the body at different time points. pk blood samples will be drawn just after the loading dose, and then just before each standard dose of vancomycin (up to 5 samples total). when possible, the pk sample may be drawn through a central venous catheter or line you already have placed, to avoid extra "needle sticks." the study staff will collect information about your health and any side effects you may be having for 7 days. length of study: treatment with vancomycin may be stopped early if you experience intolerable side effects or the doctor thinks you can stop taking the drug early. this is an investigational study. vancomycin is fda approved and commercially available for use in treating bacterial infection. the use of a loading dose for vancomycin is investigational. up to 10 patients will take part in this study. all will be enrolled at m. d. anderson.

Eligibility criteria:
inclusion criteria: 1. admission to md anderson cancer center surgical intensive care unit (sicu) under the thoracic surgery physician group 2. intravenous vancomycin therapy deemed necessary exclusion criteria: 1. age less than 18 years 2. history of hypersensitivity to vancomycin 3. patient weight greater than 150 kg 4. receival of 1 or more doses of the following agents within 72 hours prior to screening: amphotericin b (lipid, liposomal, or conventional formulation), aminoglycosides, foscarnet and/or intravenous contrast dye. 5. prior exposure (within 7 days) to intravenous vancomycin 6. current renal insufficiency defined as baseline scr \>/= 1.5 mg/dl, or increase in baseline serum creatinine (scr) by \>/= 0.5 mg/dl within the last 2 days, or estimated creatinine clearance (crcl) \</= 30 ml/min by cockcroft-gault equation. 7. current need for hemodialysis or continuous renal replacement therapy

Keywords: vancomycin pharmacokinetic testing pk
luminance red for canker sores

Conditions: Canker Sore

Summary: canker sores, also called aphthous ulcers, are small, shallow lesions that develop on the soft tissues in your mouth or at the base of your gums. unlike cold sores, canker sores don't occur on the surface of your lips and they aren't contagious. they can be painful, however, and can make eating and talking difficult. recurrent aphthous ulcer stomatitis (ras) is characterized by recurrent bouts of solitary or multiple shallow painful ulcers, at intervals of a few months to a few days in patients who are otherwise well. low level laser therapy (lllt) sometimes known as low level light therapy or photobiomodulation (pbm) is a low-intensity light therapy. the effect is photochemical not thermal. the light triggers biochemical changes within cells and can be compared to the process of photosynthesis in plants, where the photons are absorbed by cellular photoreceptors, which trigger chemical changes. the main medical usage of lllt is for pain and inflammation reduction, promoting the regeneration of different tissues and preventing damage to tissues. with the use of the appropriate power (from 5 to 200mw) and wavelength (600-900nm), the therapy brings anti-inflammatory and analgesic results aiding in wound healing. the mechanism of action of lllt may be very beneficial in the treatment of oral erosions and ulcers, however, very few studies have been performed on the treatment of ras with lllt. there are few reports on accelerated healing in erosive mucocutaneous disorders and they are often presented as a case series rather than large randomized clinical trials. the effects on skin wound healing and periodontal inflammation management with laser biostimulation suggest that this treatment modality may also be useful for oral erosive conditions. this clinical trial aims to evaluate the effect of the luminance red device on the management of ras.


Eligibility criteria:
inclusion criteria: * demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form. * 18 years and older. * self report canker sore outbreaks once every 30 days or more frequent * understands and is willing, able and likely to comply with all study procedures and restrictions. * no previous experience of lllt. * united states resident. * willingness and ability to submit a $49 deposit using a credit card for the device. exclusion criteria: * patients with a known systemic disease that predisposes them to ras (e.g., behçet disease) or undergoing systemic treatment for ras. * the presence of a serious medical condition. * currently known to be pregnant or breastfeeding * patients treated with topical or systemic medication for ras, such as corticosteroid therapy, antibiotics or analgesics during the previous month.
p1101 in treating patients with early pmf or overt pmf at low or intermediate-1 risk

Conditions: Primary Myelofibrosis; Myeloproliferative Neoplasm

Summary: this is a phase 3 double-blind clinical trial arm to test ropeginterferon alfa-2b (p1101) in adult patients with primary myelofibrosis (pmf) at early stage or low to medium risk. participants will receive the study drug/placebo bi-weekly and have an assessment visit every 4 weeks. the ratio of study drug to placebo group is 2:1.


Eligibility criteria:
inclusion criteria: 1. male or female patients aged ≥18 years at the time of signing the informed consent form; 2. patients with pre-fibrotic/early pmf (pre-pmf) or overt primary myelofibrosis at low to intermediate-1 risk according to dipss plus, diagnosed according to who 2016 or 2022 classification; 3. with good liver function at screening, which is defined as total bilirubin ≤1.5 × upper limit of normal (uln), international normalized ratio (inr) ≤1.5 × uln, albumin \&gt;3.5 g/dl, alanine aminotransferase (alt) ≤2.0 × uln, and aspartate aminotransferase (ast) ≤2.0 × uln; 4. hgb ≥10.0 g/dl at screening; 5. neutrophil count ≥1.0 × 10\^9/l at screening; 6. creatinine clearance rate ≥30 ml/min at screening (according to the cockcroft-gault formula); 7. females of childbearing potential, as well as all women \&lt;2 years after the onset of menopause, must agree to use an acceptable form of birth control until 60 days following the last dose of the study drug, and females must agree to not breastfeed during the study; 8. written informed consent obtained from the subject and ability for the subject to comply with the requirements of the study. exclusion criteria: 1. any known contraindications to interferon α or hypersensitivity to interferon α; 2. patients with prior interferon therapy having poor tolerability or lack of efficacy to the previous interferon therapy per investigator\&#39;s judgement; 3. patients with an ongoing cytoreduction (e.g., hu or ifn-α) at the time of screening if, in the investigator's opinion, randomizing them into the placebo arm will lead to immediate rebound increase of peripheral blood counts and thus may jeopardize their health status; 4. with severe or serious diseases that, in the investigator's opinion, may affect the patient's participation in this study; 5. history of major organ transplantation; 6. pregnant or breastfeeding women; 7. patients with any other diseases that will affect the study results or may weaken the compliance to protocol per the investigator's judgment; 8. use any investigational drug \&lt;4 weeks prior to the first dose of study drug, or not recovered from effects of prior administration of any investigational drug. 9. eligible for jak inhibitor therapy at screening.

Keywords: p1101 primary myelofibrosis pmf ropeginterferon pharmaessentia myeloproliferative neoplasms mpn pre-fibrotic low or intermediate-1 risk
fulfilling care needs of adolescents with cancer

Conditions: Cancer

Summary: the aim of phase 1 of this study is to develop a care need scale (cns) for adolescents with cancer. the aim of phase 2 is to examine the mediating role of care needs between physical and psychosocial dysfunction and qol, and to explore the recovery trajectory and its predictors regarding the care needs, physical and psychosocial factors, and the qol of adolescents with cancer at the first, second, and third 3-month periods after initiating on-treatment and off-treatment. the aim of phase 3 is to examine the effectiveness of the computerized assessment with graphic outcome (cago) for fulfilling the care needs of adolescents with cancer, its acceptability for adolescents with cancer, and its usability for clinicians in pediatric oncology units.


Eligibility criteria:
the inclusion criteria for adolescents with cancer are 1. 13-20 years of age 2. previously or currently treated for cancer 3. able to communicate in chinese 4. able to comprehend the study information

Keywords: cancer patients, quality of life
cold atmospheric plasma for the endoscopic treatment of duodenal polyps in patients with familial adenomatous polyposis

Conditions: Adenomatous Polyposis Coli; Familial Adenomatous Polyposis; Duodenal Adenoma

Summary: the objective of this study is to investigate the feasibility for the treatment of precancerous peri-ampullary fap polyps in the duodenum using low-thermal argonplasma.

familial adenomatous polyposis (fap) is an autosomal dominantly inherited disorder, which results from a germ line mutation in the apc (adenomatous polyposis coli) gene. fap is characterized by the formation of very high number of colorectal adenomatous polyps which could cause the development of colorectal cancer in the 5th decade of life. after colon surgery patients are still at risk of developing upper gi cancer e.g. in the duodenum. because of the continuing risk for the development of duodenal cancer, regular endoscopic surveillance is recommended for these patients. in this study a new apc modality (precise mode e1) applied for the remission of fap polyps during routine endoscopic surveillance is suggested. argonplasma coagulation (apc) is widely used for the ablation and coagulation of superficial lesions in the gi tract. the application of high thermal tissue destroying apc in the duodenum is challenging due to the anatomy of the duodenal wall which is thin and therefore susceptible to thermal damage. the application of low-thermal argonplasma in the gi tract could be just as useful as it was suggested for the treatment of neoplastic tissue in gynecology. low-thermal apc using erbe standard 3.2 mm fiapc probe and precise mode was successfully applied for the remission of cervical intraepithelial neoplasia. the formation of reactive oxygen and nitric oxide species has been discussed as trigger for the effect on neoplasia tissue of low-thermal argonplasma. regarding current knowledge this is the first application of this apc modality in the gi tract.

Eligibility criteria:
inclusion criteria: * confirmed fap disease * duodenal polyposis with recommendation of a follow-up egd in 12 months corresponding to stage iii (7-8 points) according to spigelman * presence of duodenal polyps \< 10 mm * written informed consent exclusion criteria: * presence of lesions that are suspicious of the presence of high-grade dysplasia or carcinoma * pregnancy or breastfeeding * severe general illnesses (permanent asa (american society of anesthesiologists) iii and iv) who do not prognostically benefit from follow-up, life expectancy \< 1 year * severe coagulopathy * any visible state of duodenal surface that makes apc treatment impossible, e.g. inflammation, stricture, stenosis or scarring changes/scar areas

Keywords: familial adenomatous polyposis fap duodenal adenoma argon plasma coagulation spigelman classification stage iii
effectiveness of accelerated intervention with compression sleeve in mild and moderate breast cancer-related lymphedema

Conditions: Breast Cancer; Lymphedema

Summary: the purpose of this study is to determine whether accelerated treatment with custom-made compression sleeve is more effective than standard procedure in the treatment of mild and moderate arm lymphedema secondary to primary cancer treatment.

use of a custom-made compression sleeve is an initial treatment of mild and moderate arm lymphedema secondary to primary breast cancer treatment. the compression sleeve improves the flow of lymph fluid out of the arm, reduces the swelling, and prevents progression of the lymphedema in the future. early intervention is recommended though early is not well-defined in literature. the purpose of this study is to evaluate reduction of excess limb volume and changes in arm disability and clinical symptoms in accelerated treatment with compression sleeve compared to standard treatment.

Eligibility criteria:
inclusion criteria: * participants must be refered for the first time due to unilateral arm lymphedema secondary to primary unilateral breast cancer treatment * participants must be ≥ 2 months after chemo- and radiotherapy * participants must have elv ≥10% and \ 2 cm difference between the circumference of the two arms at minimum one circumference due to lymphedema * participants must be motivated for treatment with compression sleeve and -gauntlet * participants live in and around aarhus, denmark exclusion criteria: * known metastatic disease * contraindication for treatment with compression sleeve * upper extremity deep venous thrombosis * previously use of compression sleeve * known contact allergy to latex * unable to fill in questionnaire and/or comply with treatment due to lacking danish language skills, mental state or psychological condition
the trajectory of physical activity following pulmonary rehabilitation

Conditions: COPD; Pulmonary Disease, Chronic Obstructive

Summary: pulmonary rehabilitation clearly increases exercise capacity, but its effect on physical activity in the home and community settings is less clear. it may take a longer time for this increase in physical activity to occur. it has been stated in an editorial that it takes 3 months to train the muscles but 6 months to train the brain. the investigators will first evaluate the change in physical activity following pulmonary rehabilitation using state-of-the-science motion detectors, then investigators will follow the trajectory of physical activity over the next several months.

this study will follow physical activity following pulmonary rehabilitation longitudinally over 48 weeks. investigators will use a state-of-the-art accelerometer, to analyze minutes walking per day as the primary outcome, rather than vector magnitude units (vmu) or estimated steps per day. investigators will explore potential factors influencing this important outcome, including baseline activity levels, demographic variables, changes in exercise capacity, psychological variables, and self-efficacy scores. finally, investigators will evaluate the rate of change (trajectory) in physical activity over approximately six months after pulmonary rehabilitation. there are limited data suggesting it takes time for the translation of increased exercise capacity into increased physical activity to occur.

Eligibility criteria:
inclusion criteria: 1. adults (≥ 40 years) with a primary clinical diagnosis of chronic obstructive pulmonary disease (copd) 2. a post-bronchodilator forced expiratory volume in one second(fev1)/forced vital capacity (fvc) \< 0.70 from spirometry performed within the preceding 12 months (no specific fev1 percent-predicted requirement, although we anticipate the fev1 will average around 45% of predicted, based on previous studies of pulmonary rehabilitation) 3. the patient was referred to pulmonary rehabilitation 4. the patient is clinically-stable: no exacerbation in preceding 4 weeks 5. modified medical research council (mmrc) dyspnea rating of at least 2 out of 5. exclusion criteria: 1. disease severity or co-morbidity that would make the patient be at-risk for participation this study 2. a significant movement disorder, such as hemiplegia, etc. 3. inability to read and comprehend the questionnaires, which will be in english 4. a history of poor wound healing or chronic skin conditions that might predispose to local problems from wearing the dynaport. (the dynaport can be worn outside a thin garment, such as a tee shirt, and is relatively thin, without protruding parts. however, since the device may be worn overnight, and there is a remote risk of pressure problems, this exclusion criterion was added).

Keywords: pulmonary rehabilitation
effect of cranberry extract on the urinary system

Conditions: Urinary Tract Disease; Cystitis; Antibiotic Reaction

Summary: in this study, we will try to emphasize the effects of using cranberry tablets, which is an alternative to antibiotic therapy, during uncomplicated urinary tract infections (only urinary tract, bladder and kidney infections did not).

this study was istanbul kartal dr. lütfi kırdar training and research hospital emergency medicine clinic and kırklareli training and research hospital emergency service and internal medicine polyclinic. our study; includes patients who applied to the emergency department and internal medicine outpatient clinic with the complaint of dysuria and had normal wbc, crp, urea, and creatinine values in their analysis, and leukocyturia was found in the urine test. two options were offered in the treatment to these patients. vaccinium macrocarpon aiton preparation or fosfomycin was given for seven days. the patients were asked whether their complaints had decreased according to the lykert-type verbal scale at the time of admission and on the first, third, and seventh days. when the treatment was finished, leukocytes were checked in the urinalysis. this outcome was compared between the 2 treatment options. we also noted whether nausea.

Eligibility criteria:
inclusion criteria: * older than 18 * who have urinary tract inflammation * who haven't kidney dissease previous exclusion criteria: * younger than 18 * who have kidney inflammation * pregnant patients * who have blood test abnormal (wbc, ure, creatin, crp high level)

Keywords: urinary tract disease cranberry extract antibiotic cystitis